Koyfin Home > Directory > Health Care > Biogen Inc

Biogen Inc Price Chart BIIB

Historical daily share price chart and data for Biogen Inc since 1991 adjusted for splits and dividends. The latest closing price for Biogen Inc as of October 26, 2020 is $256.76.
  • In 2020 the stock opened at $299.06 and closed at $256.76 for a loss of -16% YTD.
  • In 2019 the stock opened at $296.84 and closed at $296.73 for a loss of 0%.
  • In 2018 the stock opened at $321.15 and closed at $300.92 for a loss of -7%.
  • In 2017 the stock opened at $263.27 and closed at $318.57 for a gain of 17%.
View Chart On Koyfin

Biogen Inc Summary

Stock Symbol: BIIB

Biogen Inc Company Info

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Market Cap
39.5b
Dividend Yield
0 %
Beta vs SPX
0.85
Short Interest
301.35 %
30D Volatility
28.55
Hedge Fund Held
0 %
Competitors

Last 10 Days of BIIB Prices

10/26/2020$256.76
10/23/2020$265.00
10/22/2020$266.80
10/21/2020$268.91
10/20/2020$267.12
10/19/2020$268.77
10/16/2020$280.01
10/15/2020$280.63
10/14/2020$289.02
10/13/2020$291.46